

1 **PLANNED FUTURE STUDIES/ACTIVITIES FOR *IN VITRO* TEST METHODS FOR**  
2 **IDENTIFYING OCULAR CORROSIVES AND SEVERE IRRITANTS**

3 **1.0 BACKGROUND/INTRODUCTION**

4 In October 2003, the U.S. Environmental Protection Agency (EPA) nominated four *in vitro*  
5 test methods proposed for identifying potential ocular corrosives and severe irritants in a  
6 tiered-testing strategy for review of their current validation status. The test methods were the  
7 Bovine Corneal Opacity and Permeability (BCOP), the Hen's Egg Test - Chorioallantoic  
8 Membrane (HET-CAM) assay, Isolated Chicken Eye (ICE), and Isolated Rabbit Eye (IRE).  
9 The National Toxicology Program Interagency Center for the Evaluation of Alternative  
10 Toxicological Methods (NICEATM), in conjunction with the Ocular Toxicity Working  
11 Group (OTWG), prepared a background review document (BRD) with all available data and  
12 information supporting the current validity of each test method. The Interagency  
13 Coordinating Committee on the Validation of Alternative Methods (ICCVAM) convened an  
14 Expert Panel to assess the validation status of these *in vitro* test methods. The Expert Panel  
15 Report (ICCVAM 2005) concluded that:

- 16 • Histopathological examination should be included in the BCOP study protocol  
17 unless the test substance is from a class of materials known to be accurately  
18 predicted using only opacity and permeability.
- 19 • Histopathological examination should be considered when the current ICE test  
20 method endpoints (i.e., corneal opacity, swelling, fluorescein retention) and  
21 IRE test method endpoints (i.e., corneal opacity, swelling, fluorescein  
22 retention, epithelial integrity) produce borderline results.
- 23 • NICEATM/ICCVAM should facilitate the development of a histopathological  
24 scoring system for corneal damage (with visual aids).
- 25 • Modifications to the proposed BCOP test method protocol (i.e., use of a larger  
26 holder suggested by Ubels et al. (2002, 2004) may improve the accuracy and  
27 reliability of this test method.

28 The draft BRDs and the Expert Panel report were made available to the Scientific Advisory  
29 Committee on Alternative Toxicological Methods (SACATM) for their consideration at their

30 meeting on December 12, 2005. SACATM agreed with the conclusions of the Expert Panel.  
31 ICCVAM subsequently prepared final test method recommendations based on the Expert  
32 Panel report and SACATM comments, which will be made publicly available and provided  
33 to U.S. Federal agencies (ICCVAM 2006).

34 ICCVAM also convened a symposium, *Mechanisms of Chemically-Induced Ocular Injury*  
35 *and Recovery*, to review the state-of-the-science and understanding of the pathophysiology  
36 and mechanisms of chemically-induced ocular injury and recovery (reversibility vs.  
37 irreversibility) (<http://iccvam.niehs.nih.gov/methods/ocudocs/ocumeet/sympinfo.htm>). At  
38 that symposium, histological evaluation was recommended as a useful, additional endpoint  
39 for the BCOP, ICE, and IRE test methods (Summaries of the outcomes of the symposium are  
40 located in **Appendix A**; previously presented at SACATM meeting in December 2005).

41 Based on the conclusions in the Expert Panel Report and the recommendations at the  
42 symposium, ICCVAM concluded that histopathological evaluation of the corneal tissue,  
43 using a standardized scoring system, should be included when the BCOP, IRE, or ICE test  
44 methods are conducted. In addition, ICCVAM concluded that studies should be conducted to  
45 evaluate the impact of using a corneal holder that maintains normal curvature (e.g., the  
46 corneal mounting system designed by Ubels et al. 2002) on accuracy and/or reliability of the  
47 BCOP test method (ICCVAM 2006).

48 The following sections provide additional details regarding these proposed studies/activities,  
49 with an overall description of each project and the associated primary objectives. Because the  
50 final activity listed above (i.e., studies to evaluate the optimal corneal holder for the BCOP  
51 test method) entails a future validation study, it will be addressed in a separate document as  
52 an ICCVAM nomination for future study.

53

54 **2.0 PLANNED FUTURE STUDIES/ACTIVITIES TO BE CONDUCTED BY**  
55 **NICEATM**

56 **2.1 Creation of a Reference Atlas for the Histopathology of Chemically-Induced**  
57 **Ocular Lesions**

58 2.1.1 Description of Project

59 The proposed activity is the creation of a detailed reference atlas for histopathology of  
60 chemically-induced ocular lesions. This atlas will contain:

- 61 • a standardized protocol for the histopathological evaluation of excised corneas  
62 and enucleated eyes (e.g., preparation of ocular tissue for histology, including  
63 fixing and staining protocols; microscopic examination procedures; etc.) used  
64 in an *in vitro* ocular toxicity test method (rabbit, chicken, pig, bovine), as well  
65 as for eyes from rabbits used in *in vivo* tests
- 66 • visual aids for lesions (i.e., reference micrographs of chemically-induced  
67 ocular lesions)
- 68 • a written description of each chemically-induced lesion using standardized  
69 nomenclature

70 2.1.2 Objective

71 To create a detailed reference atlas for histopathology of chemically-induced lesions in  
72 excised corneas and enucleated eyes used in an *in vitro* ocular toxicity test method (rabbit,  
73 chicken, pig, bovine), as well as for eyes from rabbits used in *in vivo* tests.

74 2.1.3 Method/Proposed Activities

- 75 • NICEATM, working in partnership with the European Centre for the  
76 Validation of Alternative Methods (ECVAM) and the Japanese Center for the  
77 Validation of Alternative Methods (JaCVAM), will create an international  
78 working group to facilitate the collection of reference micrographs of  
79 chemically-induced ocular lesions in excised corneas and enucleated eyes  
80 used in an *in vitro* ocular toxicity test method (rabbit, chicken, pig, bovine)  
81 and from eyes of rabbits used in *in vivo* tests.

- 82           • The international working group developed by NICEATM, ECVAM, and  
83           JaCVAM will review the collection of reference micrographs of chemically-  
84           induced ocular lesions to ensure that they represent different hazard  
85           classifications, chemical classes, mechanisms of action, and other physico-  
86           chemical properties.
- 87           • These micrographs will be annotated with a standard ocular histological  
88           nomenclature and organized into an atlas, which can be used as a reference for  
89           histological evaluation of samples taken during *in vitro* and *in vivo* ocular  
90           toxicity tests.
- 91           • Data gaps in hazard classifications and pre-defined physico-chemical  
92           properties of tested chemicals, if any, will be identified during the collection  
93           of the reference micrographs.
- 94           • A strategy to fill the data gaps will be created and implemented. This could  
95           include solicitation of additional samples of chemically-induced ocular lesions  
96           from industry and private organizations.

97 2.1.4    Draft ICCVAM Recommended Priority: High

98 **2.2       Creation of a Standardized Histological Scoring System and Revised Hazard**  
99 **Classification Decision Criteria for *In Vivo* and *In Vitro* Test Methods**

100 2.2.1    Description of Project

101 The proposed activity is the creation of a standardized histological scoring system for  
102 chemically-induced ocular lesions in species used in *in vivo* (rabbit) and *in vitro* (rabbit,  
103 chicken, pig, bovine) ocular toxicity test methods. The proposed activity also includes  
104 development of revised hazard classification decision criteria, which includes the use of  
105 histopathological data, for the BCOP, ICE, and IRE test methods.

106 2.2.2    Objective

107 To create a standardized scoring system for the histopathological evaluation of chemically-  
108 induced lesions *in vivo* and in excised corneas and enucleated eyes used in *in vitro* ocular  
109 toxicity test methods, and establish revised hazard classification decision criteria for *in vivo*

110 tests and the BCOP, ICE, and IRE test methods, which would include consideration of  
111 histopathological results.

112 2.2.3 Method/Proposed Activity

- 113 • NICEATM will work in partnership with an international working group  
114 created in partnership with ECVAM and JaCVAM. NICEATM will use a  
115 detailed reference atlas of chemically-induced ocular lesions described with  
116 standard histopathological nomenclature (see **Section 2.1**), in animal species  
117 used in *in vivo* (rabbit) and *in vitro* ocular toxicity test methods (rabbit,  
118 chicken, pig, bovine), to create a standardized scoring system for the  
119 evaluation of these lesions.
- 120 • The ocular lesions in the reference atlas described in **Section 2.1** will be  
121 scored using the standardized scoring system.
- 122 • Decision criteria for the BCOP, ICE, and IRE test methods will be revised to  
123 utilize histological endpoints as a component for hazard classification.

124 2.2.4 Draft ICCVAM Recommended Priority: High

125 **3.0 ADDITIONAL ACTIVITY TO BE CONSIDERED**

126 **3.1 Development of a Targeted Research Grants Program**

127 3.1.1 Additional Background:

128 The *Mechanisms of Chemically-Induced Ocular Injury and Recovery* Symposium  
129 (<http://iccvam.niehs.nih.gov/methods/ocudocs/ocumeet/sympinfo.htm>) also focused on  
130 advancing the development of *in vitro* test systems that would meet regulatory testing  
131 requirements; provide for protection of human health; and reduce, refine, and/or replace  
132 animal use.

133 Objectives of the meeting included:

- 134 • Review current and potential molecular, cellular, tissue (e.g., histopathology),  
135 and clinical (e.g., corneal opacity, swelling, depth of injury) biomarkers of

- 136 chemical injury and recovery and their usefulness for *in vivo* and *in vitro*  
137 testing models of ocular irritancy and corrosivity.
- 138 • Identify knowledge gaps in understanding of chemically-induced ocular injury  
139 and recovery.
  - 140 • Identify and prioritize future research initiatives that would address current  
141 knowledge gaps and that are considered necessary to advance the development  
142 and validation of *in vitro* models of chemically-induced ocular injury and  
143 recovery.
  - 144 • Discuss and identify quantitative, objective endpoints that should be  
145 considered for inclusion in the current *in vivo* rabbit eye test and/or human  
146 clinical testing (e.g., more sensitive markers of injury and recovery) that  
147 would support development and validation of predictive *in vitro* methods and  
148 improve hazard characterization and reliability.

149 During the course of the symposium, several knowledge gaps that warranted further research  
150 and development were identified. These included the following potential quantitative  
151 objective endpoints or biomarkers:

- 152 • *in vivo* biomarkers (e.g., molecular, cellular, morphological, clinical) that  
153 might be predictive indicators of lesion severity
- 154 • *in vivo* biomarkers (e.g., molecular, cellular, morphological, clinical) that  
155 might be predictive indicators of reversibility, non-reversibility, or delayed  
156 responses
- 157 • modifications to current *in vitro* systems necessary for the methods to  
158 adequately predict the ocular injury potential of chemicals.

### 159 3.1.2 Description of Project:

160 The proposed activity is the development of a targeted research grants program, supported by  
161 interested stakeholders (e.g., government, industry, animal welfare organizations), to fund  
162 innovative research into high priority areas identified by experts at recent public workshops  
163 and meetings sponsored by ICCVAM, NICEATM, and ECVAM. The research grants

164 program would include, but would not necessarily be limited to, Request for Applications  
165 (RFA) and Small Business Innovative Research (SBIR) grants.

166 3.1.3 Objective:

167 Development of a research grants program, which includes the use of targeted RFAs and  
168 SBIRs, to focus research and product commercialization, respectively, for areas identified as  
169 high priority at the *Mechanisms of Chemically-Induced Ocular Injury and Recovery*  
170 Symposium. Research areas include, but are not limited to:

- 171 • Assessment of other *in vitro* test models (e.g., human, pig) as more predictive  
172 models of *in vivo* human responses to ocular injuries
- 173 • Assessment of endothelial cell damage markers as predictors of ocular  
174 corrosion and/or irritation
- 175 • Evaluation of inflammatory responses (e.g., cytokines, adhesion proteins, etc.)  
176 as markers of ocular injury
- 177 • Quantification of depth of injury in *ex vivo* models and correlation with *in*  
178 *vivo* responses
- 179 • Evaluation of cell death as a biomarker of damage and correlation with *in vivo*  
180 ocular injury
- 181 • Evaluation of alternative histopathological staining techniques to assess ocular  
182 injury
- 183 • Impact of using quantitative endpoints (e.g., slit lamp biomicroscopy with  
184 fluorescein staining, photodocumentation of injury, histopathology) on the  
185 predictive capacity and variability in response for *in vivo* studies
- 186 • Evaluation of gene expression profiling, clustering, and pathway analysis for  
187 ocular damage and repair

188 Areas of product development and commercialization might include, but not necessarily be  
189 limited to, the commercialization of alternative corneal holders for the BCOP test method,  
190 and more sensitive and predictive biomarkers of ocular injury severity and reversibility.

- 191 3.1.4 Method/Proposed Activity:
- 192 • Establish a list of high priority research areas and commercialization areas for
- 193 evaluation and potential funding
- 194 • Establish a group of interested stakeholders to develop RFAs and SBIRs for
- 195 the areas proposed for evaluation and commercialization, respectively
- 196 • Identify funding support for the RFA and SBIR
- 197 • Solicit and evaluate applications
- 198 3.1.5 Draft ICCVAM Recommended Priority: High

199 **4.0 REFERENCES**

- 200 ICCVAM Test Method Evaluation Report: In Vitro Ocular Toxicity Test Methods for
- 201 Identifying Severe Irritants and Corrosives (Available: <http://iccvam.niehs.nih.gov/>).
- 202 ICCVAM. 2005. EXPERT PANEL FINAL REPORT: Evaluation of the Current Validation
- 203 Status of In Vitro Test Methods for Identifying Ocular Corrosives and Severe Irritants
- 204 (Available: <http://iccvam.niehs.nih.gov/methods/ocudocs/EPreport/ocuEPrpt.pdf>).
- 205 Stokes WS, Tice RR, Allen DG, Choksi NY, Truax JF. The ICCVAM/NICEATM/ECVAM
- 206 symposia on mechanisms of chemically induced ocular injury and recovery
- 207 (<http://iccvam.niehs.nih.gov/methods/ocudocs/ocumeet/sympinfo.htm>).
- 208 Ubels JL, Ditlev JA, Clousing DP, Casterton PL. 2004. Corneal permeability in a redesigned
- 209 corneal holder for the bovine cornea opacity and permeability assay. Toxicol In Vitro
- 210 18:853-857.
- 211 Ubels JL, Paauw JD, Casterton PL, Kool DJ. 2002. A redesigned corneal holder for the
- 212 bovine cornea opacity and permeability assay that maintains normal corneal morphology.
- 213 Toxicol In Vitro 16:621-628.

214